We have developed a robust high-throughput automated electrophysiology assay using a monoclonal CHO-hNav1.9 cellular reagent suitable for fully supporting a Nav1.9 discovery program.
Domainex and Metrion Biosciences have formed an alliance to identify new chemical hits against ion-channel targets. Key to this collaboration are Domainex’s experience in hit identification and Metrion Bioscience’s expertise in ion channel screening and pharmacology.
The transient receptor potential cation channel A1 (TRPA1) is a voltage-dependent non-selective cation channel. It is an established therapeutic target, antagonists of which may have utility in the treatment of pain and the management of chronic cough. Bautista et al¹ described TRPA1 as a “gatekeeper of chronic inflammatory disorders of the skin, airways, and gastrointestinal tract”.
We have developed a robust high-throughput automated electrophysiology assay using a monoclonal CHO-hNav1.9 cellular reagent suitable for fully supporting a Nav1.9 discovery program.
Metrion and Sophion present findings that determine whether other insoluble salts can act as seal enhancers and how these solution pairs affect the biophysical properties and pharmacology of the investigated ion channels.